Copy to clipboard 
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
| 1Q18 | 1Q17 | $ Change | % Change | |
| Orthobiologics | $12.1 | $5.0 | $7.1 | 142.0% |
MACI also posted strong sequential growth, increasing revenue by 55% from 4Q17. The autologous cultured chondrocyte product for cartilage repair was launched in 1Q17.
Within 1Q18 came publication of results from the Phase III SUMMIT Extension study, which demonstrated that improvements in pain and function from use of MACI vs. microfracture in the treatment of knee cartilage defects were sustained for five years following surgery. The Extension is reported to be the first study in the field of cartilage repair to provide long-term, 5-year follow-up results from a successful multicenter, superiority study vs. microfracture.
Leadership recapped its four 2018 strategic imperatives for MACI, as follows:
Establish MACI as the premium cartilage repair brand.
- Via published testimonials
- Leverage SUMMIT Extension study results
Increase number of surgeons using MACI.
- Salesforce expansion: now sold by 40 reps in 5 regions (up from 28 in 4 at end of 2017)
- Investments in surgeon training; 600+ physicians trained to date, with more education on schedule
Streamline and extend MACI access.
- All of the 30 largest commercial plans now provide access to MACI; the primary focus this year is to ensure that all medical policies are updated to accurately reflect the expanded label for MACI vs. Carticel on plans that don’t already do so
Drive patient awareness.
- Launched the “It’s Your Move” direct to consumer Olympic athlete-based campaign, intended to increase initial patient interest and improve biopsy conversion rates
Source: Vericel Corporation
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
1Q18
1Q17
$ Change
% Change
Orthobiologics
$12.1
$5.0
$7.1
142.0%
MACI...
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
| 1Q18 | 1Q17 | $ Change | % Change | |
| Orthobiologics | $12.1 | $5.0 | $7.1 | 142.0% |
MACI also posted strong sequential growth, increasing revenue by 55% from 4Q17. The autologous cultured chondrocyte product for cartilage repair was launched in 1Q17.
Within 1Q18 came publication of results from the Phase III SUMMIT Extension study, which demonstrated that improvements in pain and function from use of MACI vs. microfracture in the treatment of knee cartilage defects were sustained for five years following surgery. The Extension is reported to be the first study in the field of cartilage repair to provide long-term, 5-year follow-up results from a successful multicenter, superiority study vs. microfracture.
Leadership recapped its four 2018 strategic imperatives for MACI, as follows:
Establish MACI as the premium cartilage repair brand.
- Via published testimonials
- Leverage SUMMIT Extension study results
Increase number of surgeons using MACI.
- Salesforce expansion: now sold by 40 reps in 5 regions (up from 28 in 4 at end of 2017)
- Investments in surgeon training; 600+ physicians trained to date, with more education on schedule
Streamline and extend MACI access.
- All of the 30 largest commercial plans now provide access to MACI; the primary focus this year is to ensure that all medical policies are updated to accurately reflect the expanded label for MACI vs. Carticel on plans that don’t already do so
Drive patient awareness.
- Launched the “It’s Your Move” direct to consumer Olympic athlete-based campaign, intended to increase initial patient interest and improve biopsy conversion rates
Source: Vericel Corporation
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
